Dmitriy N. Grekov

Dmitriy N. Grekov

Auto-generated profile, based on publicly available information

Dmitriy N. Grekov

Botkin Hospital

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2023 in Pirogov Russian Journal of Surgery
Verified
Journal Article
Closed access
ZBZ.A. Bagateliya
Z.A. Bagateliya
DGD.N. Grekov
D.N. Grekov
AKAnna Komarova
Anna Komarova
VKV.M. Kulushev
V.M. Kulushev
NSNikolay Юрьевич Sokolov
Nikolay Юрьевич Sokolov
MLM.S. Lebedko
M.S. Lebedko
Annual number of surgeries exceeds 10 million In Russia, and this number is increasing every year. Searching for a scale or index determining the risk of postoperative complications and mortality is an important issue all over the world. The authors analyzed all available risk assessment scales for postoperative morbidity and mortality. The most significant ones in historical aspect and modern perspective grading systems were highlighted. We compared these indices with clinical recommendations and necessary preoperative preparation. Thus, these scales are valuable for surgeons and anesthesiologists to assess the risk, volume of surgical intervention and methods of preoperative management. However, they are not perfect and require improvement. Therefore, development of such scales is a priority objective of medicine in the foreseeable future.

20 September 2022 in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
Verified
Journal Article
Open access
PDF file
ASA. V. Shabunin
A. V. Shabunin
VBV. V. Bedin
V. V. Bedin
DGD. N. Grekov
D. N. Grekov
MTM. M. Tavobilov
M. M. Tavobilov
PDP. A. Drozdov
P. A. Drozdov
VTV. A. Tsurkan
V. A. Tsurkan
Aim. To analyze the results of a multidisciplinary approach to the treatment of patients with hepatocellular cancer in a multidisciplinary oncology clinic.Materials and Methods. From 2007 to 2021, 259 patients with hepatocellular cancer were surgically treated in the Department of Liver and Pancreas Surgery of the city clinical hospital named after S.P. Botkin. Liver resections of different extent were performed in 74 (28.6%) patients, radiofrequency ablation – in 19 (7.3%), microwave ablation – in 20 (7.7%), hepatic artery chemoembolization with radiofrequency ablation – in 34 (13.1%), regional chemotherapy – in 104 (40.2%), liver transplantation – in 8 (3.1%) patients.Results. The overall five- and ten-year survival after liver resection was 51.4% and 31.1% respectively. The poor prognostic factors following liver resection were age >70 years (p = 0.03), postoperative complications (p = 0.04), lymph node metastases (p = 0.01), and a body mass index >30 kg/m2 (p = 0.045). Complications that developed after radiofrequency (microwave) ablation and chemoembolization of the hepatic artery with radiofrequency ablation were 5.1% and 5.8%. Within 90 days after liver resection, three (1.1%) patients died. Complications after resection developed in 18 (24.3%) cases during the same period. With metastases measuring ≤3 cm, the overall five-year survival after radiofrequency and microwave ablation was 36.8% and 35% respectively. With neoplasms measuring 3–5 cm, the best five-year survival was after hepatic artery chemoembolization and radiofrequency ablation (44.1%). The overall fiveyear survival after hepatic artery chemoembolization was 11.5%. No complications or deaths resulted from liver transplantation. With an average follow-up period of 12.5 months, none of the patients experienced disease recurrence or died.Conclusion. Using a multidisciplinary approach in a multidisciplinary oncology clinic improves the results of treating patients with hepatocellular cancer.

15 October 2021 in Medical alphabet
Verified
Journal Article
Closed access
PDF file
ASA. V. Shabunin
A. V. Shabunin
ERE. P. Rodionov
E. P. Rodionov
DGD. N. Grekov
D. N. Grekov
AMA. A. Malyshev
A. A. Malyshev
EEE. A. Evdokimov
E. A. Evdokimov
Technical progress facilitates to a significant increase in injuries and the severity of traumatic injuries. When providing treatment for patients with polytrauma in a multidisciplinary hospital the leading place is taken by the organization of the work of the hospital’s medical personnel, the development and implementation of standards for the guidelines specialized medical care to victims. The main priority of surgical intervention in polytrauma is to bleeding control, and staged treatment with final surgical correction after stabilization of the victim’s condition in 24–36 hours after the injury. An important role is played by standardized transfusion therapy for preventing the development of the lethal triad. Practice shows that a multidisciplinary approach is the cornerstone of providing specialized medical care for patients with polytrauma.

7 June 2024 in Surgery and Oncology
Verified
Journal Article
Open access
PDF file
ASA. V. Shabunin
A. V. Shabunin
ZBZ. A. Bagatelia
Z. A. Bagatelia
DGD. N. Grekov
D. N. Grekov
VKV. M. Kulushev
V. M. Kulushev
EKE. L. Kreneva
E. L. Kreneva
NPN. M. Podzolkova
N. M. Podzolkova
Inroduction. Polymorbidity significantly increases the risk of complications in the early postoperative period, especially in patients with colorectal cancer, taking into account the initial nutritional status disorder. At present, several scales of postoperative complications risk assessment (POSSUM, RCRI, MUST) are used, but they do not fully meet the needs of modern oncosurgery, so we consider it necessary to compare their effectiveness and propose a new integrated scale.Aim. To establish the most significant factors influencing the outcome of surgical treatment and length of hospitalization in comorbid patients with colon cancer with the development of a surgical risk assessment scale that is most adapted for this group of patients.Materials and methods. We analyzed the data of hospital charts of patients undergo surgery for colorectal cancer in the oncoproctologic department of the S. P. Botkin State Clinical Hospital of the Moscow Healthcare Department in the period from 2019 to 2022. Inclusion criteria: histologically verified colorectal adenocarcinoma; colorectal cancer in stage cT4, cN0, cM0 or cT1–4, cN1–2, cM0; presence of one or more concomitant diseases in the patient. Exclusion criteria: presence of distant metastases of colorectal cancer; absence of confirmed comorbidities; early forms of colorectal cancer (cT1–2, cN0). All patients were assessed for risk of perioperative complications using ASA, POSSUM, MUST, and RCRI scales. The study endpoints were number of days in intensive care, number of days of hospitalization, and 30-day mortality. An Excel database with POSSUM, RCRI, and MUST scale calculators was created for the study. The evaluation of parameters influencing the outcome of hospitalization was performed using ROC analysis and correlation analysis using Pearson’s criterion. To identify the most sensitive parameters affecting the outcome of hospitalization, commonly used calculators were studied in detail.Results. 200 patient records were analyzed. The results of treatment were compared with the data obtained using the postoperative risk scales POSSUM, MUST, RCRI. A comparative analysis of the scales presented above with our proposed integral scale of postoperative complications risk assessment was carried out. It was found that the parameters of our proposed integral scale showed the highest sensitivity (Se 70 %) and specificity (Sp 70 %) to the risk of postoperative complications. Our proposed integral scale showed a moderate correlation with the age of patients (r = 0.475, p = 0.01) and preoperative weight loss (r = 0.592, p = 0.01), as well as a high correlation with POSSUM (r = 0.649, p = 0.01; r = 0.852, p = 0.01) and MUST (r = 0.655, p = 0.01).Conclusion. The developed scale for assessment of surgical risk in comorbid patients with colorectal cancer showed a higher correlation with the outcome of surgical treatment than similar known scales, which indicates its effectiveness and possibility of application in clinical practice after its validation in prospective studies.

4 July 2018 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
ASA. V. Shabunin
A. V. Shabunin
MTM. M. Tavobilov
M. M. Tavobilov
DGD. N. Grekov
D. N. Grekov
PDP. A. Drozdov
P. A. Drozdov
The purpose of the study was to improve treatment outcomes for patients with inoperable colorectal liver metastases using the combination of chemoembilization of the hepatic artery and radiofrequency ablation.Material and methods. Treatment outcomes of 60 patients with methachronic unresectable liver metastases from colorectal cancer were analyzed. Eligibility criteria were as follows: absence of extrahepatic metastases, size of metastases from 3 to 5 cm, and inability to perform resection. All patients were divided into two groups. Group I included 30 patients who received combination of regional chemotherapy and radiofrequency ablation. Group II (the control group) consisted of 30 patients who received radiofrequency ablation only.Results. Post-embolization and post-ablation syndromes were observed in both groups of patients. Rightsided hydrothorax (Clavien-Dindo grade II) was found in 4 out of 60 patients (2 patients in Group I and 2 patients in Group II). One-, two- and three-year disease-free survival rates in Group I patients were 96.6 %, 76.6 % and 53.3 %, respectively. The corresponding rates in the control group patients were 90.0 %, 53.6 % and 30.0 %, respectively (p=0.049). The overall one-, two-and three-year survival rates in Group I patients were 100 %, 90 % and 63.3 %, respectively. The corresponding rates in the control group patients were 100 %, 70 % and 50.0 %, respectively (p=0.202).Conclusion. The combination of regional chemotherapy and radiofrequency ablation led to the improvement in overall and disease-free survival rates.

5 February 2024 in P.A. Herzen Journal of Oncology
Verified
Journal Article
Closed access
Konstantin TitovKonstantin Titov
Konstantin Titov
RKR.V. Karpenko
R.V. Karpenko
SLS.S. Lebedev
S.S. Lebedev
DGD.N. Grekov
D.N. Grekov
TYT.A. Yakusheva
T.A. Yakusheva
In recent decades, there has been an increase in the number of multiple primary malignant tumors. In the Russian Federation in 2021.10% of all newly diagnosed cases accounted for multiple primary tumors (58.217 cases). This is 2.12 times higher than for the same period in 2011 when 24.774 cases were recorded, constituting 4.7% of the total. Treatment of metachronous tumors often involves sequential treatment of each individual neoplasm and does not usually raise significant debates. Conversely, the treatment of synchronous tumors can be challenging. Despite advancements in cancer therapies, the issue of choosing a treatment strategy for synchronous tumors remains unresolved. There are still no unified clinical recommendations for treating this group of patients. Large randomized studies demonstrating the superiority of specific treatment methods and strategies are lacking in contemporary literature. This review analyzes the literature data on the methods used and the treatment outcomes in this group of patients.